{"id":55889,"date":"2023-01-11T12:47:03","date_gmt":"2023-01-11T12:47:03","guid":{"rendered":"https:\/\/touchoncology.com\/?post_type=media_gallery&p=55889"},"modified":"2023-01-11T12:47:03","modified_gmt":"2023-01-11T12:47:03","slug":"bernd-jilma-ash-2022-the-pathophysiology-and-unmet-treatment-needs-in-cold-agglutinin-disease","status":"publish","type":"media_gallery","link":"https:\/\/touchoncology.com\/haematology\/conference-hub\/bernd-jilma-ash-2022-the-pathophysiology-and-unmet-treatment-needs-in-cold-agglutinin-disease\/","title":{"rendered":"Bernd Jilma, ASH 2022: The pathophysiology and unmet treatment needs in cold agglutinin disease"},"content":{"rendered":"

Cold agglutinin disease (CAD) is a rare, autoimmune, clonal B cell disorder. In this touchONCOLOGY interview, we speak with<\/span> Dr Bernd Jilma <\/b>(Medical University of Vienna, Vienna, Austria) to discuss the pathophysiology of CAD and the unmet treatment needs in this disease.<\/span><\/p>\n

The abstract entitled \u2018<\/span>Trial in Progress: Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with Cold Agglutinin Disease (CASCADE)<\/span><\/a>\u2019 (Abstract #2333)\u00a0 was presented at <\/span>ASH Annual Meeting<\/span><\/a>, 10\u201313, December, 2022.<\/span><\/p>\n

Question<\/b>:<\/span><\/p>\n

Could you tell us a little about cold agglutinin disease (CAD), its pathophysiology and the unmet needs in its treatment? (0:17)<\/span><\/p>\n

Disclosures<\/b>: Bernd Jilma is on the advisory board, speaker\u2019s bureau and a consultant for Sanofi as well as having received grant\/research support and honoraria from Sanofi.\u00a0<\/span><\/p>\n

Support<\/b>: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.<\/span><\/p>\n

Filmed as a highlight of <\/i><\/b>ASH 2022<\/i><\/b><\/a><\/p>\n

Access more content on <\/i><\/b>Haematology<\/i><\/b><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Cold agglutinin disease (CAD) is a rare, autoimmune, clonal B cell disorder. In this touchONCOLOGY interview, we speak with Dr Bernd Jilma (Medical University of Vienna, Vienna, Austria) to discuss the pathophysiology of CAD and the unmet treatment needs in this disease. The abstract entitled \u2018Trial in Progress: Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 3 Study […]<\/p>\n","protected":false},"featured_media":55886,"template":"","class_list":["post-55889","media_gallery","type-media_gallery","status-publish","has-post-thumbnail","hentry","vocabulary_1-haematology","video_categories-ash-highlights"],"acf":[],"_links":{"self":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery\/55889","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery"}],"about":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/types\/media_gallery"}],"version-history":[{"count":2,"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery\/55889\/revisions"}],"predecessor-version":[{"id":55891,"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery\/55889\/revisions\/55891"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media\/55886"}],"wp:attachment":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media?parent=55889"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}